Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PHIO

PHIO - Phio Pharmaceuticals Corp Stock Price, Fair Value and News

$1.26+0.03 (+2.44%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PHIO Price Action

Last 7 days

2.4%

Last 30 days

-32.3%

Last 90 days

-38.8%

Trailing 12 Months

-55.9%

PHIO RSI Chart

PHIO Valuation

Market Cap

13.6M

Price/Earnings (Trailing)

-1.71

Price/Sales (Trailing)

738.13

EV/EBITDA

-0.43

Price/Free Cashflow

-1.86

PHIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PHIO Fundamentals

PHIO Revenue

Revenue (TTM)

21.0K

PHIO Earnings

Earnings (TTM)

-8.0M

Earnings Growth (Yr)

-56.96%

Earnings Growth (Qtr)

-10.43%

PHIO Profitability

EBT Margin

-54666.67%

Return on Equity

-80.83%

Return on Assets

-69.13%

Free Cashflow Yield

-53.7%

PHIO Investor Care

Shares Dilution (1Y)

920.11%

Diluted EPS (TTM)

-4.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240066.0K0
2019136.0K78.0K21.0K21.0K
201845.8K76.5K107.3K138.0K
201700015.0K
201610.0K19.0K19.0K19.0K
201576.0K64.0K48.0K34.0K
2014375.0K162.0K86.0K71.0K
2013172.5K248.0K323.5K399.0K
201200097.0K
20110000
Get all data in R, Python etc through our Historical Stock Data APIs

About Phio Pharmaceuticals Corp

PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEphiopharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

Phio Pharmaceuticals Corp Frequently Asked Questions

What is the ticker symbol for Phio Pharmaceuticals Corp? What does PHIO stand for in stocks?

PHIO is the stock ticker symbol of Phio Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phio Pharmaceuticals Corp (PHIO)?

As of Wed Dec 03 2025, market cap of Phio Pharmaceuticals Corp is 13.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHIO stock?

You can check PHIO's fair value in chart for subscribers.

Is Phio Pharmaceuticals Corp a good stock to buy?

The fair value guage provides a quick view whether PHIO is over valued or under valued. Whether Phio Pharmaceuticals Corp is cheap or expensive depends on the assumptions which impact Phio Pharmaceuticals Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHIO.

What is Phio Pharmaceuticals Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, PHIO's PE ratio (Price to Earnings) is -1.71 and Price to Sales (PS) ratio is 738.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Phio Pharmaceuticals Corp's stock?

In the past 10 years, Phio Pharmaceuticals Corp has provided -0.703 (multiply by 100 for percentage) rate of return.